Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

Drug Development

Stock Dives as Celldex Cuts 20% of Staff After Phase II Breast Cancer Failure

On April 16, Celldex Therapeutics reported that its Phase IIb trial of glembatumumab vedotin (glemba) failed in a trial of metastatic triple-negative breast cancer. Now the company has filed with the U.S. Securities and Exchange Commission (SEC) that it is cutting about 20 percent of staff.

April 25, 2018

3 min read

Mark Terry

BioForest

Companies Showcase Good News for Patients at AAN

This year’s American Academy of Neurology meeting in Los Angeles has revealed positive news that can benefit patients across a wide variety of indications.

April 24, 2018

2 min read

Alex Keown

Drug Development

Eli Lilly’s Arthritis Drug Gets Mixed Recommendation, But Reports Strong Quarter

Last week, the FDA’s advisory committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis expressed safety concerns. Not surprisingly, the Arthritis Advisory Committee’s recommendation yesterday was mixed, split right along safety concerns.

April 24, 2018

3 min read

Mark Terry

Black clock with Review time, three-dimensional rendering, 3D illustration

Policy

Eli Lilly and Incyte Shares Drop as FDA Raises Concerns about Arthritis Drug

Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.

April 19, 2018

2 min read

Mark Terry

Drug Development

Amgen’s Migraine Drug Heads Toward Possible May Approval

Amgen announced final data from its Phase IIIb LIBERTY clinical trial of Aimovig (erenumab), with positive results likely to lead to a blockbuster drug for migraine sufferers.

April 18, 2018

3 min read

Mark Terry

Business

Eli Lilly Shows Off More Verzenio Data at AACR

Nearly two months after Eli Lilly secured an expanded approval indication for its cancer drug Verzenio, the company unveiled final data from the MONARCH 3 trial that won the latest nod from the U.S. Food and Drug Administration for the treatment of some breast cancer patients.

April 18, 2018

3 min read

Alex Keown

Business

Terns Pharmaceuticals Taps 2 Scientific Advisors as it Eyes the Clinic for its New NASH Programs

Less than one week after licensing three non-alcoholic steatohepatitis (NASH) programs from Eli Lilly, startup company Terns Pharmaceuticals has strengthened its leadership team with the appointment of two scientific advisors.

April 13, 2018

2 min read

Alex Keown

Laboratory work at a blank steril bank. Cell splitting work.

Business

New Biotech Incubator Will Have New Business Model

Alexandria Real Estate Equities, an urban office real estate investment company specializing in the life sciences, is expanding its Alexandria LaunchLabs into the East Cambridge, Massachusetts area.

April 12, 2018

2 min read

Mark Terry

Why Bristol-Myers' Future is Highly Dependent on T

Genetown

Bristol-Myers Squibb and Harvard Stem Cell Institute Team Up

Bristol-Myers Squibb and the Harvard Fibrosis Network, part of the Harvard Stem Cell Institute, have launched a collaboration to discover and develop new therapies for fibrotic diseases.

April 12, 2018

3 min read

Mark Terry

JOBS